Epirus Biopharmaceuticals Company Profile (NASDAQ:EPRS)

About Epirus Biopharmaceuticals

Epirus Biopharmaceuticals logoEPIRUS Biopharmaceuticals, Inc. (Epirus) is a biopharmaceutical company. The Company focuses on biosimilars, which are biologic drugs. Its segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. The Company's products include BOW015, a biosimilar version of Remicade, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a); BOW050, a biosimilar version of Humira, which is an inhibitor of TNF-a used to treat inflammatory diseases; BOW070, a biosimilar version of Actemra, which is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis; BOW090, a biosimilar version of STELARA, which is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis; BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare blood disorders.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EPRS
  • CUSIP:
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $0.33
  • 200 Day Moving Average: $1.83
  • 52-Week Range: $0.08 - $6.76
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.31
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Beta: 2.52
Additional Links:
Companies Related to Epirus Biopharmaceuticals:

Analyst Ratings

Consensus Ratings for Epirus Biopharmaceuticals (NASDAQ:EPRS) (?)
Ratings Breakdown: 3 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $7.33 (4,788.89% upside)

Analysts' Ratings History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Show:
DateFirmActionRatingPrice TargetDetails
5/15/2016Leerink SwannDowngradeOutperform -> Market PerformView Rating Details
5/11/2016BTIG ResearchDowngradeBuy -> NeutralView Rating Details
5/11/2016WedbushDowngradeOutperform -> Neutral$11.00 -> $2.00View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/13/2016        
3/15/2016Q415($0.56)($0.63)ViewListenView Earnings Details
11/16/2015Q315($0.51)($0.59)$221.00 millionViewListenView Earnings Details
8/7/2015Q215($0.38)($0.65)ViewN/AView Earnings Details
5/12/2015Q1($0.43)($0.39)ViewN/AView Earnings Details
3/23/2015Q414($0.99)($0.80)ViewN/AView Earnings Details
11/10/2014($0.43)($1.28)ViewN/AView Earnings Details
8/20/2014($1.20)($1.52)ViewN/AView Earnings Details
5/9/2014Q114$0.20($0.15)$9.00 million$1.60 millionViewN/AView Earnings Details
3/13/2014($0.14)($0.29)ViewN/AView Earnings Details
11/4/2013Q313($0.50)($0.46)$3.66 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.07)($0.08)$2.91 million$3.89 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.07)($0.06)$3.44 million$3.70 millionViewN/AView Earnings Details
3/6/2013Q4 2012($0.08)($0.06)$3.12 million$3.67 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Current Year EPS Consensus Estimate: $-0.96 EPS
Next Year EPS Consensus Estimate: $-0.49 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.66)($0.40)($0.53)
Q2 20162($0.52)($0.26)($0.39)
Q3 20162($0.43)($0.16)($0.30)
Q4 20162($0.27)($0.15)($0.21)
Q1 20171($0.16)($0.16)($0.16)
Q2 20171($0.12)($0.12)($0.12)
Q3 20171($0.11)($0.11)($0.11)
Q4 20171($0.11)($0.11)($0.11)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/21/2015Robert TicktinGeneral CounselBuy3,000$3.72$11,160.00View SEC Filing  
12/17/2015Aurentz VincentInsiderBuy2,200$3.43$7,546.00View SEC Filing  
12/16/2015Amit MunshiCEOBuy8,270$2.80$23,156.00View SEC Filing  
12/15/2015Amit MunshiCEOBuy8,069$2.87$23,158.03View SEC Filing  
12/9/2015Amit MunshiCEOBuy13,190$4.07$53,683.30View SEC Filing  
12/9/2015Aurentz VincentInsiderBuy2,800$3.85$10,780.00View SEC Filing  
9/21/2015Amit MunshiCEOBuy10,000$6.19$61,900.00View SEC Filing  
9/18/2015Amit MunshiCEOBuy10,000$5.99$59,900.00View SEC Filing  
2/6/2015Montreux Equity Partners Iv LpMajor ShareholderSell167,316$5.00$836,580.00View SEC Filing  
2/4/2015Montreux Equity Partners Iv LpMajor ShareholderSell52,684$4.98$262,366.32View SEC Filing  
2/4/2015Scott M RocklageDirectorBuy400,000$5.00$2,000,000.00View SEC Filing  
1/26/2015Montreux Equity Partners Iv LpMajor ShareholderSell38,516$6.47$249,198.52View SEC Filing  
1/23/2015Montreux Equity Partners Iv LpMajor ShareholderSell22,530$6.29$141,713.70View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Epirus Biopharmaceuticals (NASDAQ:EPRS)
DateHeadline
News IconAre Analysts Optimistic About Where EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) is Heading? - Winfield Review (NASDAQ:EPRS)
winfieldreview.com - February 24 at 10:54 PM
News IconAre Analysts Forecasting a Near-Term Upswing For EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS)? - Wall Street Beacon (NASDAQ:EPRS)
wsbeacon.com - February 1 at 5:37 PM
News IconEarnings in Full Force, Analysts Take Aim at EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - Wall Street Beacon (NASDAQ:EPRS)
wsbeacon.com - January 27 at 6:41 PM
News IconEPIRUS Biopharmaceuticals, Inc. (EPRS) Under Analyst Spotlight - UK Market News (NASDAQ:EPRS)
www.ukmarketnews.co.uk - January 25 at 3:45 AM
News IconGearing Up For a Bull Run? Analysts Weigh in on EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - Wall Street Beacon (NASDAQ:EPRS)
wsbeacon.com - January 19 at 3:27 AM
News IconWill The Needle Move For EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:EPRS)
wsbeacon.com - January 13 at 3:58 PM
News IconPrice Change to Note: What Next for EPIRUS BIOPHARMACEUTICALS INCORPORATED (EPRSQ) Stock - Thorold News (NASDAQ:EPRS)
www.whatsonthorold.com - December 29 at 10:09 PM
News IconPrice Action to Note: Could EPIRUS BIOPHARMACEUTICALS INCORPORATED (EPRSQ) See a Reversal? - Thorold News (NASDAQ:EPRS)
www.whatsonthorold.com - December 16 at 5:33 PM
News IconOTC Stock Watching: Could EPIRUS BIOPHARMACEUTICALS INCORPORATED (EPRSQ) Skyrocket From Here? - Thorold News (NASDAQ:EPRS)
www.whatsonthorold.com - December 12 at 5:14 PM
News IconToday's OTC Stock Alert: How Analysts Feel About EPIRUS BIOPHARMACEUTICALS INCORPORATED (EPRSQ)? - Thorold News (NASDAQ:EPRS)
www.whatsonthorold.com - December 7 at 3:21 PM
News IconOTC Stock Coverage: Time to Reconsider EPIRUS BIOPHARMACEUTICALS INCORPORATED (EPRSQ)? - Thorold News (NASDAQ:EPRS)
www.whatsonthorold.com - December 1 at 5:06 PM
News IconOTC Stock Summary: Is EPIRUS BIOPHARMACEUTICALS INCORPORATED (EPRSQ) a Buy? The Stock Is in ... - Thorold News (NASDAQ:EPRS)
www.whatsonthorold.com - November 24 at 6:55 AM
News IconOTC Stock Filing: What's Ahead for EPIRUS BIOPHARMACEUTICALS INCORPORATED (EPRSQ) - Thorold News (NASDAQ:EPRS)
www.whatsonthorold.com - November 10 at 1:26 PM
News IconOTC Stock Watching: What's Ahead for EPIRUS BIOPHARMACEUTICALS INCORPORATED (EPRSQ) - Thorold News (NASDAQ:EPRS)
www.whatsonthorold.com - November 7 at 4:50 PM
News IconBroker Changes For EPIRUS Biopharmaceuticals, Inc. (EPRS) - NewsDen (NASDAQ:EPRS)
newsden.net - October 16 at 4:45 PM
News IconHC Stocks Summary= Galena Biopharma Inc (NASDAQ:GALE ... - share market updates (press release) (NASDAQ:EPRS)
sharemarketupdates.com - September 8 at 8:44 AM
News IconHC Stocks Assessment: Epirus Biopharmaceuticals Inc (NASDAQ:EPRS), AstraZeneca plc (ADR) (NYSE:AZN) - share market updates (press release) (NASDAQ:EPRS)
sharemarketupdates.com - August 18 at 10:12 PM
istreetwire.com logoStocks To Watch: EPIRUS Biopharmaceuticals, Inc. (EPRS), Visa Inc. (V), Merck & Co. Inc. (MRK) - iStreetWire (NASDAQ:EPRS)
istreetwire.com - August 2 at 9:40 AM
biz.yahoo.com logoEPIRUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rul (NASDAQ:EPRS)
biz.yahoo.com - August 1 at 4:47 PM
investing.com logoU.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.01% (NASDAQ:EPRS)
www.investing.com - July 29 at 11:54 AM
istreetwire.com logoStock's Trend Analysis Report: EPIRUS Biopharmaceuticals, Inc. (EPRS), American Airlines Group Inc. (AAL ... - iStreetWire (NASDAQ:EPRS)
istreetwire.com - July 26 at 4:53 PM
streetinsider.com logoEPIRUS Biopharma (EPRS) Enters Livzon Satisfaction Amendment; Files for Chapter 7 Bankruptcy - StreetInsider.com (NASDAQ:EPRS)
www.streetinsider.com - July 25 at 10:22 PM
streetinsider.com logoEPIRUS Biopharma (EPRS) Enters Livzon Satisfaction Amendment; Files for Chapter 7 Bankruptcy (NASDAQ:EPRS)
www.streetinsider.com - July 25 at 4:53 PM
biz.yahoo.com logoEPIRUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Bankruptcy or Receive (NASDAQ:EPRS)
biz.yahoo.com - July 25 at 11:32 AM
4-traders.com logoLion Biotechnologies : Biotechnology Stocks Technical Data -- EPIRUS Biopharma, Ampio Pharma, Spark Therapeutics, and Lion Biotechnologies (NASDAQ:EPRS)
www.4-traders.com - July 21 at 8:22 AM
News IconBiotechnology Stocks Technical Data -- EPIRUS Biopharma, Ampio Pharma, Spark Therapeutics, and Lion Biotechnologies (NASDAQ:EPRS)
www.kswo.com - July 21 at 8:22 AM
News IconEpirus Biopharmaceuticals Inc (NASDAQ:EPRS): Down, But Perhaps Not Out - Insider Financial (NASDAQ:EPRS)
www.insiderfinancial.com - July 18 at 4:59 PM
News IconHC Stocks Zone: Gilead Sciences, Inc. (NASDAQ:GILD), Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) - share market updates (press release) (NASDAQ:EPRS)
sharemarketupdates.com - July 15 at 7:29 AM
istreetwire.com logo3 Notable Runners: EPIRUS Biopharmaceuticals, Inc. (EPRS), Johnson & Johnson (JNJ), Pandora Media, Inc. (P) - iStreetWire (NASDAQ:EPRS)
istreetwire.com - July 11 at 4:51 PM
News IconHC Stocks Highlights: Epirus Biopharmaceuticals Inc (NASDAQ:EPRS), AstraZeneca plc (ADR) (NYSE:AZN) - share market updates (press release) (NASDAQ:EPRS)
sharemarketupdates.com - July 7 at 4:54 PM
News IconHC Stocks Summary: Galena Biopharma Inc (NASDAQ:GALE), Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) - share market updates (press release) (NASDAQ:EPRS)
sharemarketupdates.com - July 6 at 4:57 PM
proactiveinvestors.co.uk logoDow Jones suffers triple-digit fall (NASDAQ:EPRS)
www.proactiveinvestors.co.uk - July 6 at 9:35 AM
investors.com logoUS stocks nurse losses as post-Brexit hurts oil prices (NASDAQ:EPRS)
www.proactiveinvestors.com - July 6 at 9:35 AM
benzinga.com logoStocks Hitting 52-Week Lows - Benzinga (NASDAQ:EPRS)
www.benzinga.com - July 5 at 4:45 PM
capitalcube.com logoETF’s with exposure to EPIRUS Biopharmaceuticals, Inc. : July 1, 2016 (NASDAQ:EPRS)
www.capitalcube.com - July 1 at 6:10 PM
biz.yahoo.com logoEPIRUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Mate (NASDAQ:EPRS)
biz.yahoo.com - July 1 at 5:23 PM

Social

What is Epirus Biopharmaceuticals' stock symbol?

Epirus Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EPRS."

Where is Epirus Biopharmaceuticals' stock going? Where will Epirus Biopharmaceuticals' stock price be in 2017?

3 brokerages have issued twelve-month price targets for Epirus Biopharmaceuticals' stock. Their forecasts range from $2.00 to $10.00. On average, they anticipate Epirus Biopharmaceuticals' share price to reach $7.33 in the next year.

When will Epirus Biopharmaceuticals announce their earnings?

Epirus Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, May, 13th 2016.

How do I buy Epirus Biopharmaceuticals stock?

Shares of Epirus Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Epirus Biopharmaceuticals stock cost?

One share of Epirus Biopharmaceuticals stock can currently be purchased for approximately $0.15.

Epirus Biopharmaceuticals (NASDAQ:EPRS) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Epirus Biopharmaceuticals (NASDAQ:EPRS)

Earnings History Chart

Earnings by Quarter for Epirus Biopharmaceuticals (NASDAQ:EPRS)

Dividend History Chart

Dividend Payments by Quarter for Epirus Biopharmaceuticals (NASDAQ:EPRS)

Last Updated on 2/25/2017 by MarketBeat.com Staff